Answers are grounded in this paper and cite their sources.
Randomized trial evaluates GnRHa and lauromacrogol effects on ovarian reserve and pain in patients with endometriotic cysts, indicating better outcomes with combined treatment.
Objectives: To evaluate the efficacy of gonadotropin-releasing hormone agonist (GnRHa) combined with lauromacrogol sclerotherapy in preserving ovarian reserve and reducing pain in patients with ovarian endometriotic cysts (OECs). Methods: Eighty OEC patients (Oct 2020–Oct 2024) were randomized into two groups ( n = 40 each). The control group received laparoscopic cystectomy, and the observation group was treated with GnRHa plus lauromacrogol sclerotherapy. Curative effects were compared. Results: The total effective rate of the observation group (95.00%, 95% CI: 87.2–98.9) was higher than that of the control group (77.50%, 95% CI: 65.1–86.8; OR=5.51, 95% CI: 1.21–15.56, P < 0.05). After treatment, serum FSH, LH, E2, CA125, CA199 levels and VAS scores in the observation group were lower than those in the control group (all P < 0.05). The recurrence rate of the observation group (5.00%) was lower than that of the control group (17.<0.05). Conclusion: The combination of GnRHa and lauromacrogol sclerotherapy has a significant effect on OEC, which can improve ovarian reserve function, reduce pain scores and recurrence rates.
No takes yet. Share an insight, caveat, or question.
Song et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: